Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24961317 | 0.78 | — | — | |
| SCHEMBL8548278 | 0.71 | — | — | |
| SCHEMBL845771 | 0.71 | — | — | |
| SCHEMBL29875992 | 0.71 | — | — | |
| SCHEMBL25876440 | 0.69 | — | — | |
| SCHEMBL25135413 | 0.67 | — | — | |
| SCHEMBL11271152 | 0.66 | CYP2C19 (0.31) | CYP2C19 | |
| SCHEMBL9089091 | 0.66 | CYP2C19 (0.31) | CYP2C19 | |
| SCHEMBL23072739 | 0.62 | — | — | |
| SCHEMBL19250736 | 0.62 | USP2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360740-A1 | HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9724321-B2 | Histone deacetylase inhibitors | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160143874-A1 | HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-05-26 | — | — | US | disclosed |
| US-9199923-B2 | Histone deacetylase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-12-01 | — | — | US | disclosed |
| US-20150038581-A1 | HISTONE DEACETYLASE INHIBITORS | Harvard University & Medical School | 2015-02-05 | — | — | US | disclosed |
| US-20140213620-A1 | HISTONE DEACETYLASE INHIBITORS | BRADNER JAMES ELLIOT (US) | 2014-07-31 | — | — | US | disclosed |
| US-8754237-B2 | Bifunctional histone deacetylase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-17 | — | — | US | disclosed |
| US-8383855-B2 | Histone deacetylase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-02-26 | — | — | US | disclosed |
| US-20130018103-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-8304451-B2 | Histone deacetylase and tubulin deacetylase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-11-06 | — | — | US | disclosed |
| US-8222423-B2 | Bifunctional histone deacetylase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8178579-B2 | Histone deacetylase inhibitors; anticancer agents; antiprotozoa agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100093842-A1 | Laulimalide Analogs and Uses Thereof | EISAI CO. LTD. | 2010-04-15 | — | — | US | disclosed |
| US-20100056588-A1 | HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2010-03-04 | — | — | US | disclosed |
| US-20090312363-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-12-17 | — | — | US | disclosed |
| US-20090209590-A1 | Histone Deacetylase and Tubulin Deacetylase Inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-08-20 | — | — | US | disclosed |
| US-20080269245-A1 | Dioxanes and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2008-10-30 | — | — | US | disclosed |
| US-20070287745-A1 | Laulimalide Analogs and Uses Thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-12-13 | — | — | US | disclosed |
| US-7244853-B2 | Dioxanes and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-07-17 | — | — | US | disclosed |
| US-20040072849-A1 | Dioxanes and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018103-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC2 | CYP2C19 4283/4885 |
| US-20100093842-A1 | Laulimalide Analogs and Uses Thereof | LPXN, MLX, ZYX | CYP2C19 4226/4885 |
| US-20140213620-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | CYP2C19 2392/4885 |
| US-20160143874-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | CYP2C19 2236/4885 |
| US-20090312363-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC2 | CYP2C19 4283/4885 |
| US-20090209590-A1 | Histone Deacetylase and Tubulin Deacetylase Inhibitors | HDAC6, HDAC1, HDAC5 | CYP2C19 4460/4885 |
| US-20170360740-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | CYP2C19 2392/4885 |
| US-20040072849-A1 | Dioxanes and uses thereof | UTS2R, HDAC5, AMDHD2 | CYP2C19 3756/4885 |
| US-20070287745-A1 | Laulimalide Analogs and Uses Thereof | LPXN, MLX, ZYX | CYP2C19 4226/4885 |
| US-20150038581-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | CYP2C19 2392/4885 |
| US-20100056588-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | CYP2C19 2392/4885 |
| US-20080269245-A1 | Dioxanes and uses thereof | UTS2R, MAN2B2, AMDHD2 | CYP2C19 3323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.